Literature DB >> 35524749

Oral Glucose Tolerance Test Measures of First-phase Insulin Response and Their Predictive Ability for Type 1 Diabetes.

David A Baidal1, Megan Warnock2, Ping Xu3, Susan Geyer4, Jennifer B Marks1, Antoinette Moran5, Jay Sosenko1, Carmella Evans-Molina6.   

Abstract

CONTEXT: Decreased first-phase insulin response (FPIR) during intravenous glucose tolerance testing (IVGTT) is an early indicator of β-cell dysfunction and predictor of type 1 diabetes (T1D).
OBJECTIVE: Assess whether oral glucose tolerance test (OGTT) measures could serve as FPIR alternatives in their ability to predict T1D in autoantibody positive (Aab+) subjects.
DESIGN: OGTT and IVGTT were performed within 30 days of each other. Eleven OGTT variables were evaluated for (1) correlation with FPIR and (2) T1D prediction.
SETTING: Type 1 Diabetes TrialNet "Oral Insulin for Prevention of Diabetes in Relatives at Risk for T1D" (TN-07) and Diabetes Prevention Trial-Type 1 Diabetes (DPT-1) studies clinical sites. PATIENTS: TN-07 (n = 292; age 9.4 ± 6.1 years) and DPT-1 (n = 194; age 15.1 ± 10.0 years) Aab + relatives of T1D individuals. MAIN OUTCOME MEASURES: (1) Correlation coefficients of OGTT measures with FPIR and (2) T1D prediction at 2 years using area under receiver operating characteristic (ROCAUC) curves.
RESULTS: Index60 showed the strongest correlation in DPT-1 (r = -0.562) but was weaker in TN-07 (r = -0.378). C-peptide index consistently showed good correlation with FPIR across studies (TN-07, r = 0.583; DPT-1, r = 0.544; P < 0.0001). Index60 and C-peptide index had the highest ROCAUCs for T1D prediction (0.778 vs 0.717 in TN-07 and 0.763 vs 0.721 in DPT-1, respectively; P = NS), followed by FPIR (0.707 in TN-07; 0.628 in DPT-1).
CONCLUSIONS: C-peptide index was the strongest measure to correlate with FPIR in both studies. Index60 and C-peptide index had the highest predictive accuracy for T1D and were comparable. OGTTs could be considered instead of IVGTTs for subject stratification in T1D prevention trials.
© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  C-peptide index; Index60; TrialNet; first-phase insulin response; oral glucose tolerance test; type 1 diabetes

Mesh:

Substances:

Year:  2022        PMID: 35524749      PMCID: PMC9282258          DOI: 10.1210/clinem/dgac285

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   6.134


  25 in total

1.  Longitudinal study on pubertal insulin resistance.

Authors:  M I Goran; B A Gower
Journal:  Diabetes       Date:  2001-11       Impact factor: 9.461

2.  A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants.

Authors:  Jay M Sosenko; Jeffrey Mahon; Lisa Rafkin; John M Lachin; Heidi Krause-Steinrauf; Jeffrey P Krischer; David Cuthbertson; Jerry P Palmer; Clinton Thompson; Carla J Greenbaum; Jay S Skyler
Journal:  Pediatr Diabetes       Date:  2011-03       Impact factor: 4.866

3.  Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial.

Authors:  Jeffrey P Krischer; Desmond A Schatz; Brian Bundy; Jay S Skyler; Carla J Greenbaum
Journal:  JAMA       Date:  2017-11-21       Impact factor: 56.272

4.  Effects of insulin in relatives of patients with type 1 diabetes mellitus.

Authors: 
Journal:  N Engl J Med       Date:  2002-05-30       Impact factor: 91.245

5.  Predictive value of intravenous glucose tolerance test insulin secretion less than or greater than the first percentile in islet cell antibody positive relatives of type 1 (insulin-dependent) diabetic patients.

Authors:  P Vardi; L Crisa; R A Jackson
Journal:  Diabetologia       Date:  1991-02       Impact factor: 10.122

6.  Diagnosis of pre-type I diabetes.

Authors:  H P Chase; M A Voss; N Butler-Simon; S Hoops; D O'Brien; M J Dobersen
Journal:  J Pediatr       Date:  1987-12       Impact factor: 4.406

7.  First-degree relatives of patients with type I diabetes mellitus. Islet-cell antibodies and abnormal insulin secretion.

Authors:  S Srikanta; O P Ganda; A Rabizadeh; J S Soeldner; G S Eisenbarth
Journal:  N Engl J Med       Date:  1985-08-22       Impact factor: 91.245

8.  Islet cell antibody-positive versus -negative phenotypic type 2 diabetes in youth: does the oral glucose tolerance test distinguish between the two?

Authors:  Hala Tfayli; Fida Bacha; Neslihan Gungor; Silva Arslanian
Journal:  Diabetes Care       Date:  2009-12-22       Impact factor: 17.152

9.  Relationships between insulin secretion after intravenous and oral glucose administration in subjects with glucose tolerance ranging from normal to overt diabetes.

Authors:  A Mari; A Tura; G Pacini; A Kautzky-Willer; E Ferrannini
Journal:  Diabet Med       Date:  2008-06       Impact factor: 4.359

10.  Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels.

Authors:  Kristina M Utzschneider; Ronald L Prigeon; Mirjam V Faulenbach; Jenny Tong; Darcy B Carr; Edward J Boyko; Donna L Leonetti; Marguerite J McNeely; Wilfred Y Fujimoto; Steven E Kahn
Journal:  Diabetes Care       Date:  2008-10-28       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.